Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study assessing safety, pharmacokinetics, and pharmacodynamics of inhaled QBW276 in patients with pulmonary cystic fibrosis; study completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis Pulmonary

Drugs mentioned

• QBW276

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Cystic Fibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-17